Trial · NCT02948426
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Maximum Tolerated Dose of Intraperitoneal Autologous Monocytes | All Participants On Dose Level 1 Through Dose Level 4 | 750000000 | Cells | ||
| Overall Maximum Tolerated Dose of Sylatron (Peginterferon Alpha-2b) | All Participants On Dose Level 1 Through Dose Level 4 | 250 | mcg | ||
| Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b) | All Participants On Dose Level 1 Through Dose Level 4 | 50 | mcg | ||
| Number of Participants With a Response | Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml) | Complete Response | 0 | Participants | |
| Number of Participants With a Response | Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Complete Response | 0 | Participants | |
| Number of Participants With a Response | Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Complete Response | 0 | Participants | |
| Number of Participants With a Response | Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml) | Complete Response | 0 | Participants | |
| Number of Participants With a Response | Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml) | Partial Response | 1 | Participants | |
| Number of Participants With a Response | Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Partial Response | 0 | Participants | |
| Number of Participants With a Response | Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Partial Response | 0 | Participants | |
| Number of Participants With a Response | Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml) | Partial Response | 1 | Participants | |
| Number of Participants With a Response | Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml) | Stable Disease | 0 | Participants | |
| Number of Participants With a Response | Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Stable Disease | 2 | Participants | |
| Number of Participants With a Response | Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Stable Disease | 1 | Participants | |
| Number of Participants With a Response | Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml) | Stable Disease | 2 | Participants | |
| Number of Participants With a Response | Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml) | Progressive Disease | 1 | Participants | |
| Number of Participants With a Response | Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Progressive Disease | 4 | Participants | |
| Number of Participants With a Response | Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml) | Progressive Disease | 2 | Participants | |
| Number of Participants With a Response | Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml) | Progressive Disease | 3 | Participants | |
| Time to Disease Progression | Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml) | 3.7 | Full Range 1 to 8 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02948426/results